Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma
Lymphoma, Large B-Cell, Diffuse
Positron Emission Tomography Computed Tomography
(18)F-FLT PET after 1-2 cycles of chemotherapy predicts PFS and OS, and a negative (18)F-FLT iPET result may potentially help design risk-adapted therapies in patients with aggressive lymphomas. In contrast, the positive predictive value of (18)F-FLT iPET remains too low to justify changes in patient management.